Table 1
Clinical features of eight patients. All patients were overweight
| Patient | Age | Sex | Main symptom | Duration | Treatment | Outcome | Refractive error | V acuity | Field loss | Grade papilloedema10 |
Associations | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (Fig1A) | 27 | F | postural TVO | 2 months new | acetazolamide | resolution off treatment | emm both eyes | 6/6 R | nasal | 5 | ||
| 6/6 L | ||||||||||||
| 2 (Fig 1B) | 34 | F | headache | 1 month new | acetazolamide | resolution off treatment | emm both eyes | 6/6 | nasal | 1 | ||
| 6/6 | ||||||||||||
| 3 (Fig 1C) | 20 | F | headache | 3 months new | acetazolamide | resolution off treatment | +0.75 both eyes | 6/6 | nasal | 2 | ||
| scintillations | 6/6 | |||||||||||
| 4 (Fig 1D) | 49 | F | headache | 7 months chronic | acetazolamide | shunt failure medical treatment | emm both eyes | 6/6 | constriction nasal | 3 | ||
| blurred vision | frusemide | 6/9 | ||||||||||
| shunt | ||||||||||||
| 5 (Fig 1E) | 23 | F | headache | 1 week recurrent | acetazolamide | resolution off treatment | +0.5 both eyes | 6/6 | normal Goldmann | 1 | ||
| 6/6 | ||||||||||||
| 6 (Fig 1F) | 22 | F | headache | 1 month recurrent | acetazolamide | resolution off treatment | +1.0 both eyes | 6/6 | normal Goldmann | 1 | ||
| 6/6 | ||||||||||||
| 7 (Fig 1G) | 36 | M | metamorphopsia | 2 years chronic | acetazolamide | chronic symptoms | emm RE | 6/6 | nasal central LE | 3 | nephrotic syndrome hypertension | |
| +1.0 LE | 6/12 | |||||||||||
| 8 (Fig1H) | 39 | F | headache | 1 year chronic | acetazolamide | chronic headache + | +1.00 RE | 6/6 | constriction | 2 | ||
| TVO LE | frusemide | TVO | +2.00 LE | 6/9 | ||||||||
-
TVO = transient visual obscurations. Emm = emmetropic.
